A detailed history of 683 Capital Management, LLC transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, 683 Capital Management, LLC holds 3,000,000 shares of ADGI stock, worth $9.93 Million. This represents 0.9% of its overall portfolio holdings.

Number of Shares
3,000,000
Previous 3,625,000 17.24%
Holding current value
$9.93 Million
Previous $12 Million 17.24%
% of portfolio
0.9%
Previous 1.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
N/A
-625,000 Reduced 17.24%
3,000,000 $9.93 Million
Q2 2024

Aug 14, 2024

BUY
N/A
150,000 Added 4.32%
3,625,000 $12 Million
Q1 2024

May 15, 2024

SELL
N/A
-125,000 Reduced 3.47%
3,475,000 $11.5 Million
Q4 2023

Feb 14, 2024

SELL
N/A
-400,000 Reduced 10.0%
3,600,000 $11.9 Million
Q2 2023

Aug 14, 2023

BUY
N/A
600,000 Added 17.65%
4,000,000 $13.2 Million
Q1 2023

May 15, 2023

BUY
N/A
400,000 Added 13.33%
3,400,000 $11.3 Million
Q4 2022

Feb 14, 2023

SELL
$3.08 - $4.05 $1.2 Million - $1.58 Million
-390,000 Reduced 11.5%
3,000,000 $9.93 Million
Q3 2022

Nov 14, 2022

SELL
$2.97 - $4.83 $634,501 - $1.03 Million
-213,637 Reduced 5.93%
3,390,000 $10.6 Million
Q2 2022

Aug 15, 2022

BUY
$2.54 - $4.52 $3.18 Million - $5.67 Million
1,253,637 Added 53.35%
3,603,637 $11.8 Million
Q1 2022

May 16, 2022

BUY
$3.81 - $10.77 $6.59 Million - $18.6 Million
1,730,000 Added 279.03%
2,350,000 $10.7 Million
Q4 2021

Feb 14, 2022

BUY
$6.35 - $47.04 $3.94 Million - $29.2 Million
620,000 New
620,000 $4.5 Million

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track 683 Capital Management, LLC Portfolio

Follow 683 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 683 Capital Management, LLC with notifications on news.